Imunon, Inc. (IMNN)
0.6231
-0.01
(-0.94%)
USD |
NASDAQ |
Nov 16, 13:48
Imunon Shareholders Equity (Quarterly) : 2.622M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 2.622M |
| June 30, 2026 | 4.189M |
| March 31, 2026 | 3.360M |
| December 31, 2025 | 7.062M |
| September 30, 2025 | 4.082M |
| June 30, 2025 | 2.660M |
| March 31, 2025 | 0.452M |
| December 31, 2024 | 4.244M |
| September 30, 2024 | 8.192M |
| June 30, 2024 | 3.741M |
| March 31, 2024 | 8.500M |
| December 31, 2023 | 13.39M |
| September 30, 2023 | 18.07M |
| June 30, 2023 | 21.52M |
| March 31, 2023 | 26.65M |
| December 31, 2022 | 29.33M |
| September 30, 2022 | 41.35M |
| June 30, 2022 | 47.04M |
| March 31, 2022 | 46.27M |
| December 31, 2021 | 55.80M |
| September 30, 2021 | 59.34M |
| June 30, 2021 | 64.05M |
| March 31, 2021 | 54.96M |
| December 31, 2020 | 18.61M |
| September 30, 2020 | 18.66M |
| Date | Value |
|---|---|
| June 30, 2020 | 24.21M |
| March 31, 2020 | 16.21M |
| December 31, 2019 | 14.56M |
| September 30, 2019 | 15.46M |
| June 30, 2019 | 18.83M |
| March 31, 2019 | 21.40M |
| December 31, 2018 | 20.86M |
| September 30, 2018 | 15.13M |
| June 30, 2018 | 19.15M |
| March 31, 2018 | 23.61M |
| December 31, 2017 | 26.70M |
| September 30, 2017 | 5.287M |
| June 30, 2017 | 6.649M |
| March 31, 2017 | 6.106M |
| December 31, 2016 | 6.726M |
| September 30, 2016 | 10.57M |
| June 30, 2016 | 16.51M |
| March 31, 2016 | 15.31M |
| December 31, 2015 | 20.39M |
| September 30, 2015 | 25.08M |
| June 30, 2015 | 29.11M |
| March 31, 2015 | 26.70M |
| December 31, 2014 | 32.83M |
| September 30, 2014 | 38.92M |
| June 30, 2014 | 45.36M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Altimmune, Inc. | 443.57M |
| Taysha Gene Therapies, Inc. | 356.97M |
| Agenus, Inc. | -105.37M |
| Amgen, Inc. | 14.35B |
| Anika Therapeutics, Inc. | 137.58M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 12.01M |
| Total Liabilities (Quarterly) | 9.386M |
| Debt to Equity Ratio | 2.646 |
| Current Ratio | 1.377 |
| Net Debt Paydown Yield | -14.34% |